A generic image of a stock chart
Markets

Pra Health Sciences Inc (PRAH) President & CEO Colin Shannon Sold $29.9 million of Shares

President & CEO of Pra Health Sciences Inc ( PRAH ) Colin Shannon sold 400,000 shares of PRAH on 08/14/2017 at an average price of $74.85 a share. The total sale was $29.9 million.

PRA Health Sciences Inc is a United State based full-service global contract research organization. It provides a broad range of product development services for pharmaceutical and biotechnology companies around the world. PRA Health Sciences Inc has a market cap of $4.71 billion; its shares were traded at around $75.16 with a P/E ratio of 48.45 and P/S ratio of 2.49.

CEO Recent Trades:

  • President & CEO Colin Shannon sold 400,000 shares of PRAH stock on 08/14/2017 at the average price of $74.85. The price of the stock has increased by 0.41% since.

CFO Recent Trades:

  • Executive VP & CFO Linda Baddour sold 100,000 shares of PRAH stock on 08/14/2017 at the average price of $74.85. The price of the stock has increased by 0.41% since.

Directors and Officers Recent Trades:

  • 10% Owner Fund Holdings Gp Ltd Kkr sold 9,500,000 shares of PRAH stock on 08/14/2017 at the average price of $74.85. The price of the stock has increased by 0.41% since.
  • 10% Owner Pra Investors L.p. Kkr sold 9,500,000 shares of PRAH stock on 08/14/2017 at the average price of $74.85. The price of the stock has increased by 0.41% since.

click here

.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PRAH

Other Topics

Stocks